VORICONAZOLE ACCORDPHARMA 50 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

voriconazole accordpharma 50 mg tabletti, kalvopäällysteinen

accord healthcare b.v. accord healthcare b.v. - voriconazolum - tabletti, kalvopäällysteinen - 50 mg - vorikonatsoli

VORICONAZOLE ACCORDPHARMA 200 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

voriconazole accordpharma 200 mg tabletti, kalvopäällysteinen

accord healthcare b.v. accord healthcare b.v. - voriconazolum - tabletti, kalvopäällysteinen - 200 mg - vorikonatsoli

Pemetrexed Baxter Euroopan unioni - suomi - EMA (European Medicines Agency)

pemetrexed baxter

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiset aineet - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Xalkori Euroopan unioni - suomi - EMA (European Medicines Agency)

xalkori

pfizer europe ma eeig - crizotinib - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Pemetrexed Pfizer (previously Pemetrexed Hospira) Euroopan unioni - suomi - EMA (European Medicines Agency)

pemetrexed pfizer (previously pemetrexed hospira)

pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiset aineet - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Teysuno Euroopan unioni - suomi - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafur, gimeracil, oteracil - mahalaukun kasvaimet - antineoplastiset aineet - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Mycophenolate Mofetil Accord 250 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

mycophenolate mofetil accord 250 mg kapseli, kova

accord healthcare b.v. - mofetil mycophenolate - kapseli, kova - 250 mg - mykofenolihappo

Cisplatin Accord 1 mg/ml infuusiokonsentraatti, liuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

cisplatin accord 1 mg/ml infuusiokonsentraatti, liuosta varten

accord healthcare b.v. - cisplatin - infuusiokonsentraatti, liuosta varten - 1 mg/ml - sisplatiini

IMATINIB KOANAA 100 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

imatinib koanaa 100 mg tabletti, kalvopäällysteinen

koanaa healthcare gmbh - imatinibi mesylas - tabletti, kalvopäällysteinen - 100 mg - imatinibi

IMATINIB KOANAA 400 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

imatinib koanaa 400 mg tabletti, kalvopäällysteinen

koanaa healthcare gmbh - imatinibi mesylas - tabletti, kalvopäällysteinen - 400 mg - imatinibi